The specific role of chemokines in atherosclerosis
The specific role of chemokines in atherosclerosis
复制标题
DOI：
10.1160/th07-01-0036
复制
发表时间：
2007-05-01
影响因子：
6.7
通讯作者：
Steffens, Sabine
中科院分区：
文献类型：
--
作者：
Braunersreuther, Vincent;Mach, Francois;Steffens, Sabine
动脉粥样硬化是一种慢性炎症性疾病，是心脏病和中风的主要病因。内膜中炎症细胞的募集是动脉粥样硬化发生和发展的关键步骤。这一过程是由活化的内皮细胞和炎症细胞局部产生趋化因子和趋化因子受体所触发的。CC趋化因子家族的多个成员（如MCP - 1/CCL2）以及CXC家族（如IL - 8/CCL8、IP - 10/CXCL10、SDF - 1/CXCL12），以及最近的 fractalkine/CX3CL1都与动脉粥样硬化的发展有关。动物模型的最新研究结果表明，阻断趋化因子/趋化因子受体相互作用可能是治疗动脉粥样硬化的一种合适方法。同样，抑制白细胞募集的趋化因子拮抗剂对于治疗动脉粥样硬化的主要后果——心肌梗死所引发的炎症可能特别有意义。
Atherosclerosis is a chronic inflammatory disease that represents the primary cause of heart disease and stroke.The recruitment of inflammatory cells in the intima is an essential step in the development and progression of atherosclerosis. This process is triggered by local production of chemokines and chemokine receptors from activated endothelial cells and inflammatory cells. Various members of the CC chemokine family (e.g. MCP-I/CCL2) as well as CXC family (e.g. IL-8/CCL8, IP-10/CXCL10, SDF-1/CXCL12) and, more recently, fractalkine/CX3CLI have been implicated in atherosclerosis development. Latest findings in animal models suggest that blocking chemokine/chemokine receptor interactions may serve as a suitable approach to treat atherosclerosis. Likewise, chemokine antagonists that inhibit leukocyte recruitment could particularly be interesting to treat inflammation in response to myocardial infarction, the major consequence of atherosclerosis.